|
시장보고서
상품코드
1698069
흡입 일산화질소 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 용도별, 지역별, 경쟁별(2020-2030년)Inhaled Nitric Oxide Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Region and Competition, 2020-2030F |
||||||
세계의 흡입 일산화질소 시장 규모는 2024년에 7억 3,212만 달러에 달하며, 2030년까지 CAGR은 7.12%로, 예측 기간 중 강력한 성장이 예측됩니다.
세계의 흡입 일산화질소(iNO) 시장은 다양한 호흡기 및 심혈관 질환의 관리에 있으며, 매우 중요한 역할을 하고 있으며, 헬스케어 및 제약 산업에서 중요한 분야로 부상하고 있습니다. 무색, 무취의 기체인 흡입용 일산화질소는 혈관 확장 및 항염증 효과로 인해 널리 인정받고 있으며, 필수적인 치료 옵션으로 자리 잡았습니다. 만성폐쇄성폐질환(COPD), 천식, 급성호흡곤란증후군(ARDS) 등 호흡기 질환의 유병률 증가로 인해 시장이 크게 성장하고 있습니다. 흡입용 일산화질소는 신생아의 천성 폐고혈압증 치료에 사용되는 등 신생아과에서 용도가 확대되고 있으며, 시장 확대에 크게 기여하고 있습니다. 예를 들어 미국 식품의약국(FDA)은 흡입형 일산화질소 시스템의 승인 및 사용에 대한 엄격한 가이드라인을 시행하고 있으며, 여기에는 광범위한 임상시험과 시판 후 감시가 포함됩니다. CERCLA(Comprehensive Environmental Response, Compensation and Liability Act)는 일산화질소를 유해물질로 분류하고 있으며, 신중한 취급과 폐기를 요구하고 있습니다. 이러한 규제는 국제적으로도 적용되므로 전 세계에 진출하는 시장 진출 기업에게는 더욱 큰 도전이 되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 7억 3,212만 달러 |
| 시장 규모 : 2030년 | 10억 9,727만 달러 |
| CAGR : 2025-2030년 | 7.12% |
| 급성장 부문 | 천식·COPD |
| 최대 시장 | 북미 |
시장은 흡입 일산화질소 치료의 새로운 용도를 탐색하고 효능을 향상시키기 위한 연구개발 활동이 급증하고 있습니다. 제약사들은 COVID-19 관련 호흡기 합병증 치료와 같은 기존 용도 외의 다른 질환에 대한 일산화질소 흡입제의 적용 가능성을 평가하기 위한 임상시험에 적극적으로 참여하고 있습니다. 이러한 용도의 다양화는 혁신을 촉진하고 시장 성장을 가속하고 있습니다.
호흡기질환의 유병률 상승
높은 치료 비용
원격의료와 원격 환자 모니터링의 부상
Global Inhaled Nitric Oxide Market was valued at USD 732.12 million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.12% through 2030. The Global Inhaled Nitric Oxide (iNO) Market has emerged as a critical sector within the healthcare and pharmaceutical industry, playing a pivotal role in the management of various respiratory and cardiovascular disorders. Inhaled Nitric Oxide, a colorless and virtually odorless gas, has gained widespread recognition for its vasodilatory and anti-inflammatory properties, making it an essential therapeutic option. The market is witnessing significant growth due to the increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory distress syndrome (ARDS). The expanding applications of inhaled nitric oxide in neonatology, where it is employed to treat persistent pulmonary hypertension in newborns, contribute substantially to market expansion. For instance, in the U.S., the Food and Drug Administration (FDA) enforces strict guidelines for the approval and use of inhaled nitric oxide systems, which include extensive clinical trials and post-market surveillance. The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) classifies nitric oxide as hazardous, requiring meticulous handling and disposal. These regulations are also applicable internationally, creating additional challenges for market participants operating globally.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 732.12 Million |
| Market Size 2030 | USD 1097.27 Million |
| CAGR 2025-2030 | 7.12% |
| Fastest Growing Segment | Asthma and COPD |
| Largest Market | North America |
The market is characterized by a surge in research and development activities, aiming to explore novel applications and enhance the efficacy of inhaled nitric oxide therapies. Pharmaceutical companies are actively engaged in clinical trials to assess the feasibility of inhaled nitric oxide in addressing conditions beyond its conventional use, such as in the treatment of COVID-19-related respiratory complications. This diversification of applications is fostering innovation and driving market growth.
Key Market Drivers
Rising Prevalence of Respiratory Disorders
The rising prevalence of respiratory disorders stands as a primary catalyst propelling the global inhaled nitric oxide (iNO) market to unprecedented heights. Over the past few years, there has been a noticeable surge in the incidence of respiratory conditions worldwide, creating an urgent demand for innovative and effective treatment modalities. Conditions such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary hypertension have become more prevalent, necessitating advanced therapeutic interventions. For instance, the Centers for Disease Control and Prevention reported that in 2022, approximately 1 in every 10 infants born in the U.S. was preterm. Preterm birth, defined as delivering a baby before 37 weeks of pregnancy, presents substantial health risks to infants, including respiratory distress syndrome and persistent pulmonary hypertension.
Inhaled nitric oxide has emerged as a crucial player in the healthcare sector, offering a promising solution for managing and improving outcomes in patients with respiratory disorders. Its vasodilatory effects and ability to enhance oxygenation make it particularly valuable in the treatment of conditions where respiratory function is compromised. The global healthcare landscape is witnessing a paradigm shift with an increasing focus on addressing respiratory health issues, and inhaled nitric oxide has positioned itself at the forefront of this transformative wave. For instance, according to April 2021 statistics from the Asthma and Allergy Foundation of America, approximately 20 million adults aged 18 and older in the United States suffer from asthma. This high prevalence of respiratory disorders in the country creates a steady demand for inhaled nitric oxide, contributing to the growth of the market in the United States.
Key Market Challenges
High Cost of Inhaled Nitric Oxide Treatment
The intricate processes involved in the production, storage, and delivery of inhaled nitric oxide contribute to the elevated overall treatment expenses. The cost-intensive nature of these procedures poses a challenge to the affordability of inhaled nitric oxide treatment, particularly in regions where healthcare budgets are constrained. Striking a delicate balance between ensuring profitability for manufacturers and affordability for healthcare systems is imperative for the sustained growth of the market.
The high cost of inhaled nitric oxide treatment exacerbates global disparities in healthcare access. Regions with limited financial resources may find it challenging to integrate this therapeutic option into their healthcare systems, potentially leaving patients without access to a treatment that could significantly improve their respiratory conditions. Bridging this accessibility gap requires concerted efforts to develop pricing models that accommodate diverse economic landscapes.
Key Market Trends
Rise Of Telehealth and Remote Patient Monitoring
The rise of telehealth and remote patient monitoring is playing a pivotal role in boosting the Global Inhaled Nitric Oxide (iNO) Market. As healthcare continues to evolve, telehealth platforms and remote monitoring technologies have become integral components in the management of respiratory disorders, contributing significantly to the growth of inhaled nitric oxide therapies. Telehealth facilitates virtual consultations, allowing healthcare providers to remotely assess patients' respiratory conditions, discuss symptoms, and make informed decisions about treatment plans. In the context of inhaled nitric oxide, this trend enables healthcare professionals to monitor patients' responses to treatment in real-time, adjusting dosages or interventions as necessary. This remote monitoring capability not only enhances the efficiency of healthcare delivery but also ensures that patients receive timely and personalized care, particularly in the management of chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) or asthma.
In this report, the Global Inhaled Nitric Oxide Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Inhaled Nitric Oxide Market.
Global Inhaled Nitric Oxide Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: